trending Market Intelligence /marketintelligence/en/news-insights/trending/z4uW1V3dI2Mlj3B-f6k88A2 content esgSubNav
In This List

Marinus seeks to raise $65M via common stock offering, private placement

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Marinus seeks to raise $65M via common stock offering, private placement

Marinus Pharmaceuticals Inc. plans to raise about $65 million in gross proceeds from a public offering of its common stock and a concurrent private placement.

The Radnor, Pa.-based pharmaceuticals company is offering 28 million shares for $1.25 each as part of its underwritten public offering. Underwriters have also been given a 30-day option to buy up to an additional 4.2 million common shares from the company, Marinus said in a Dec. 11 press release.

Meanwhile, certain investors have agreed to purchase a total of $30 million worth of preferred shares.

Net proceeds from the common stock offering and the private placement will be primarily used to further the clinical development of the company's postpartum depression drug ganaxolone, which failed to best placebo during the second part of a mid-stage clinical trial in July.

Oppenheimer & Co. Inc. and Ladenburg Thalmann & Co. Inc. were the joint book-running managers, while Craig-Hallum Capital Group LLC acted as co-manager for the offering, expected to close Dec. 13.